Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Regimen shows promise as salvage for classical HL

Publish date:: February 22, 2019

Key clinical point: Brentuximab vedotin plus ifosfamide, gemcitabine, and vinorelbine (BV-IGEV) appears effective as salvage for patients with relapsed/refractory classical Hodgkin lymphoma.

Major finding: Of 28 patients, 27 responded to BV-IGEV.

Study details: A retrospective study of 28 patients.

Disclosures: The authors reported having no conflicts of interest.

Citation:

Abuelgasim KA et al. Bone Marrow Transplant. 2019 Jan 30. doi: 10.1038/s41409-019-0454-z.

This Week's Must Reads

Women Underrepresented as Oncology Trial Corresponding Authors,

Professional Coaching Keeps Physicians in the Game,

CMS Plans to Give MIPS an Overhaul,

Conflicts of Interest Common Among Authors of ASCO Guidelines,

Hospital Price Transparency Proposal Misses the Mark,

Must Reads in Hodgkin Lymphoma

Regimen shows promise as salvage for classical HL,

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.